ECG-Excellence

ECG Excellence is a biotechnology and information technology startup founded in 2019 and headquartered in The Netherlands. The company's slogan "We support patients and medical professionals in providing better, earlier, lower costs non-invasive cardiac diagnostics" reflects its core mission. ECG Excellence specializes in developing and delivering technology to advance healthcare, particularly in the field of ECG morphology diagnostics and prognosis. By integrating 3D imaging and software into standard 12 lead ECG recording devices, the company is able to detect cardiac issues before symptoms manifest. Their unique, patented technology adds value by identifying genetic-related, individual-related, and co-morbid cardiac diseases, such as those linked to diabetes.

The most recent investment in ECG Excellence amounted to €125.00K through a Convertible Note on 14 February 2022. As the company is still in the developmental phase and conducting tests on its technology, it presents an intriguing opportunity for venture capital. With its innovative approach to non-invasive cardiac diagnostics and a focus on improving patient outcomes while reducing costs, ECG Excellence may have the potential to significantly impact the healthcare and biotechnology sectors. Investors interested in participating in the future of advanced cardiac diagnostics should closely monitor ECG Excellence's progress and consider potential involvement in upcoming funding rounds.